Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections

Chronic pulmonary methicillin-resistant Staphylococcus aureus (MRSA) disease in cystic fibrosis (CF) has a high probability of recurrence following treatment with standard-of-care antibiotics and represents an area of unmet need associated with reduced life expectancy. We developed a lipoglycopeptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Plaunt, Adam J., Rose, Sasha J., Kang, Jeong Yeon, Chen, Kuan-Ju, LaSala, Daniel, Heckler, Ryan P., Dorfman, Arielle, Smith, Barrett T., Chun, Donald, Viramontes, Veronica, Macaluso, Antonio, Li, Zhili, Zhou, Yuchen, Mark, Lilly, Basso, Jessica, Leifer, Franziska G., Corboz, Michel R., Chapman, Richard W., Cipolla, David, Perkins, Walter R., Malinin, Vladimir S., Konicek, Donna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373216/
https://www.ncbi.nlm.nih.gov/pubmed/33941518
http://dx.doi.org/10.1128/AAC.00316-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373216/
https://www.ncbi.nlm.nih.gov/pubmed/33941518
http://dx.doi.org/10.1128/AAC.00316-21

Ejemplares similares